Alivexis Secures 800M JPY in Series D Funding.

Deal News | Jan 10, 2025 | Fast Track Initiative Inc

Fast Track Initiative, a life science venture capital firm, announced its involvement in a Series D funding round for Alivexis, a company focusing on rapid drug discovery through cutting-edge computational technologies. Alivexis, originally Modulus Discovery, raised 800 million JPY in this round, elevating its total capital raised to approximately 6.66 billion JPY. The funds are earmarked for advancing over ten proprietary drug discovery programs and enhancing its ModBind platform. Established in 2016, Alivexis aims to deliver innovative treatments for cancer and other serious conditions. FTI, established in 2004, focuses on early-stage biotech and therapeutic startups, supporting them through strategy, partnerships, and its network.

Sectors

Biotechnology
Venture Capital

Geography

Japan – Alivexis is headquartered in Tokyo, Japan, and Fast Track Initiative operates within the Japanese market.
United States – Alivexis also has an operational foundation in the United States.

Industry

Biotechnology – Alivexis specializes in drug discovery utilizing advanced bio-computational technologies.
Venture Capital – Fast Track Initiative is a venture capital firm investing in early-stage biotechnology and life sciences companies.

Financials

800M JPY – Amount raised by Alivexis in the first closing of its Series D funding round.
6.66B JPY – Total capital raised by Alivexis post the Series D funding round.

Participants

Name	Role	Type	Description
Alivexis	Target Company	Company	A pioneering biotechnology company focused on small-molecule therapeutics.
Fast Track Initiative, Inc.	Investor	Company	A venture capital firm specializing in life sciences and biotechnology investments.
Roy S. Kimura	Chief Executive Officer	Person	CEO of Alivexis, leading innovative drug discovery initiatives.
Kazuki Ohno	Chief Operating Officer	Person	COO of Alivexis, involved in operational leadership.
Tomo Anzai	Managing Partner and External Board of Director	Person	Managing Partner at FTI and an external board director at Alivexis, representing FTI's interests.